TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Condition: Carcinoma, Hepatocellular Interventions: Drug: Lenvatinib; Procedure: TACE Sponsor: Zhejiang Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Research